Polyclonal serum-free light chains elevation in HIV-infected patients

AIDS

Volumn 26, Issue 16, 2012, Pages 2107-2110

  Bibas, Michele ^a   Lorenzini, Patrizia ^a   Cozzi Lepri, Alessandro ^b   Calcagno, Andrea ^c   Di Giambenedetto, Simona ^d   Costantini, Andrea ^e   Castagna, Antonella ^f   Manfrin, Vinicio ^g   Monforte, Antonella D ^h   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g Azienda Sanitaria Ulss 6 Vicenza   (Italy)

^h SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; SERUM FREE LIGHT CHAIN; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 84867744620     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328358d54b     Document Type: Article

References (12)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24:1537-1548.
3. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1 infected patients treated with antiretroviral therapy, 1996-2006 collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
4. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376:49-62.
5. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 2011; 5:171-186.
6. Bibas M. Polyclonal serum free light chains: a biomarker of disease prognosis or of immune senescence? J Clin Oncol 2012; July 9. [Epub ahead of print]
7. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 2011; 57:1387-1389.
8. Nakano T, Matsui M, Inoue I, Awata T, Katayama S, Murakoshi T. Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta 2011; 412:843-849.
9. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 28: 773-779.
10. Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, et al. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lym-phoma and its correlation with antiretroviral therapy. Am J Hematol 2012; 87:749-753; doi: 10.1002/ajh.23236.
11. Katzmann JA, Clarck RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains:relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48:1437-1444.
12. Bradwell AR. Immunoglobuliln free light chains and their analysis. Chapter 5: Normal ranges and reference interval. In Serum Free Light Chain Analysis (plus Hevylite), 6th edn. The Binding Site Group Ltd. 2010; pp: 36-44.